

Klaus Hoeflich, PhD Chief Scientific Officer

Klaus serves as Chief Scientific Officer at Nested Therapeutics, a new biotech company focused on discovering the next generation of precision oncology medicines. Prior to his current role, Klaus was senior vice president and head of biological sciences at Blueprint Medicines, and senior scientist and program leader at Genentech. Klaus has 20 years of experience in R&D, contributed to the development of four FDA-approved cancer medicines, and authored more than 70 scientific articles. He obtained his PhD degree in medical biophysics from the University of Toronto and has been awarded a Medical Research Council of Canada's Next Generation Award.